GlassScriptPhysician profile
Bela Shestopalova
NPI 1205918802
$3,823.78
in general payments reported to CMS, 2019-2025
25 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $381 · 2021: $2,008 · 2022: $550 · 2023: $253 · 2024: $230 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,244.01 | 2021 | |
| Vanda Pharmaceuticals INC. | $571.94 | 2021-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $480.89 | 2020-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $372.38 | 2020-2024 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $214.43 | 2019-2024 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $208.30 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $147.52 | 2022-2023 | Seglentis |
| Paratek Pharmaceuticals, INC. | $83.18 | 2021 | |
| Ironwood Pharmaceuticals, INC | $80.46 | 2020 | |
| Allergan, INC. | $51.16 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $46.22 | 2022 | |
| Pfizer INC. | $45.65 | 2021 | |
| Amgen INC. | $39.85 | 2025 | Repatha |
| Janssen Pharmaceuticals, INC | $29.03 | 2019 | |
| Eisai INC. | $25.18 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $23.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.92 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $22.88 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.24 | 2019 | |
| Genentech USA, INC. | $18.24 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.88 | 2024 | Xifaxan |
| Astellas Pharma US INC | $15.75 | 2023 | Veozah |
| Avion Pharmaceuticals | $15.73 | 2021 | |
| Phadia US INC. | $13.03 | 2019 | |
| Glaxosmithkline, LLC. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bela Shestopalova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.